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Otospongiosis is a primary osteodystrophy of the otic capsule that affects genetically predisposed 
individuals and leads to a progressive hearing loss.
Aim: To evaluate the applicability of audiometric evaluation during drug treatment for otospongiosis. 
Materials and Methods: A prospective, randomized, controlled, double-blind study involving 26 
patients with clinical, audiometric and CT scan image of otosclerosis. Patients eligible for the study 
were divided into three groups (A, B and C) and received treatment with alendronate sodium (B), 
sodium fluoride (C) and placebo (A) for 6 months. After this period they were submitted to new tests. 
Results: There were not statistically significant differences between air and bone conduction (gap). 
We also found no differences in the speech recognition threshold (SRT) and speech discrimination 
(IRF) between before and after treatment.
Conclusion: After six months of drug treatment the audiometric evaluation kept the same hearing 
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INTRODUCTION
Otospongiosis is a primary focal osteodystrophy 
of the ear capsule that affects genetically predisposed 
individuals and introduces a metabolic disorder on the 
endochondral layer of the labyrinth bone characterized 
by resorption and disorganized new bone growth.
This disease presents no symptoms in most 
cases. However, under certain circumstances, it may 
compromise the stapediovestibular joint and lead to 
progressive conductive hearing loss. In some cases, the 
disease may be more aggressive and injure and inner 
ear’s sensorineural structures, thus producing mixed or 
even sensorineural dysacusis.
Many theories have been tried to explain the 
injuries to the inner ear causes by otospongiosis, such 
as: release of toxic enzymes into the fluids of the in-
ner ear; vascular shunts between otosclerotic sites and 
labyrinthine vessels; atrophy in the organ of Corti and 
in the stria vascularis; hyalinization of the spiral liga-
ment; narrowing of the cochlear lumen; distortions in 
the basilar membrane; and degeneration of cochlear 
nerve cells1.
The enzyme theory seems to be more widely 
accepted in the literature. Proteolytic and hydrolytic 
enzymes are released by lysosomes rupturing inside 
histiocytes found in the active otospongiosis site, thus 
adversely affecting the labyrinthine neuroepithelium2-5.
Given the progressively degenerative character-
istics of otospongiosis, it became necessary to resort 
to drugs to limit the disease’s activity. The use of bone 
metabolism inhibitors aims at providing for the preser-
vation of hearing thresholds (sensorineural component)
and improving symptoms such as tinnitus and vertigo.
Along the years, experimental and clinical trials 
have tried to show the positive effects of fluoride in 
stabilizing hearing thresholds in patients with otospon-
giosis and improving associated symptoms such as tin-
nitus and vertigo2,5-10. Drug therapy for otospongiosis 
with sodium fluoride is, undoubtedly, the most widely 
prescribed treatment for this condition by ENT physi-
cians. This drug principally reduces enzyme activity 
derived from otospongiosis, aside from diminishing the 
rate of osteoblast-induced bone remodelling10.
Shambaugh & Scott11 were the first to use so-
dium fluoride to treat osteodystrophy and propose the 
prescription of moderate doses of this drug to promote 
recalcification and deactivation of the active otospon-
giosis sites.
Double-blind controlled clinical trials have also 
shown the efficacy of sodium fluoride in stabilizing hear-
ing thresholds (sensorineural component of hearing)9-12,14.
Some authors have observed that the treatment 
with sodium fluoride could diminish the progression of 
sensorineural hearing loss, mainly in higher frequen-
cies5.
Given their better anti-resorption properties and 
closer affinity with bone tissue, biphosphonates have 
replaced sodium fluoride in the treatment of osteodys-
trophies such as Paget’s disease, osteogenesis imper-
fecta, and osteoporosis. Following this therapeutic line, 
biphosphonates also began to be used to treat otospon-
giosis. Stutzmann & Petrovic13 were the first to propose 
that otospongiosis be treated with biphosphonates.
Biphosphonates interact with osteoclast metabo-
lism to induce osteoclast apoptosis, thus inhibiting bone 
resorption. By that same mechanism, the production of 
toxic enzymes is reduced secondarily to abnormal bone 
metabolism15. These drugs have been considered to be 
the most promising medication to treat otospongiosis16.
Kennedy et al.17 carried out a double-blind pro-
spective study to assess disodium etidronate in treating 
progressive hearing loss in otospongiosis patients. The 
group given etidronate tended to have their air conduc-
tion hearing thresholds stabilized at 1000 and 4000 Hz 
while bone conduction thresholds were stabilized at 
500, 1000 and 2000 Hz (there was no statistically signifi-
cant difference between the case and control groups).
A retrospect ive study done by Brook-
ler & Tanyeri18 observed that etidronate (a first 
generation biphosphonate) appeared to be more effec-
tive in managing otoneurologic symptoms introduced 
by otospongiosis (hearing loss, tinnitus, and vertigo) 
than sodium fluoride.
An experimental tr ial carr ied out with 
genetically modified mice with inhibited expression of 
osteoprotegerin (OPG - a glycoprotein that blocks the 
formation of osteoclasts and inhibits osteolysis) showed 
that biphosphonates (zolendronate and risedronate) 
significantly suppressed remodelling and resorption in 
the ear capsule and reduced hearing loss according to 
hearing electrophysiological test results. The authors 
suggested that these drugs could be useful in preventing 
hearing loss associated with otosclerosis19.
This study aims to verify the application of au-
diometric assessment along with the drug therapy given 
to otospongiosis patients.
MATERIALS AND METHODS
This is a randomized double-blind controlled 
prospective trial with 26 patients diagnosed with 
otospongiosis through medical, audiometric, and CT 
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imaging examination. This study was approved by 
the Research Ethics Committee of our institution (CEP 
0114/05), as well as the terms of the informed consent 
form.
The patients were submitted to medical 
examination (interview, ENT examination) and 
audiometry testing (pure-tone audiometry, speech au-
diometry, and impedance tests).
Patients of both genders with ages ranging be-
tween 20 and 70 years were enrolled in the study. All 
were medically examined and suspected for otospongio-
sis, had normal otoscopy findings, audiometry indicative 
of otospongiosis and high-resolution CT scans showing 
active otospongiosis. None of the patients had history 
of surgery in the examined ear.
Pregnancy, presence of chronic infection/inflam-
mation, esophageal or gastric diseases, metal prosthesis, 
pacemakers, intolerance or adverse reactions to the 
prescribed medication, and use of anti-resorption or 
anti-enzymatic drugs 12 months prior to the study were 
used as exclusion criteria.
Eligible patients were randomized into three 
groups (A, B, and C) and were treated for six months 
with sodium alendronate, sodium fluoride, or placebo. 
Patients, treatments, and analysis were masked.
Both medication (10mg sodium alendronate and 
20mg sodium fluoride) and placebo pills were produced 
at the Pharmaceutical Laboratory of the University of São 
Paulo (USP) and analyzed at the Medication, Cosmetics, 
and Raw Material Control Laboratory at USP (CONFAR) 
(Analysis Certificate nr. 1281/07 and 1674/07).
The patients underwent audiometry testing after 
the completion of the drug therapy.
Audiometry Testing
Hearing thresholds by air (AC) and bone conduc-
tion (BC) before and after treatment were acquired for 
frequencies between 500 and 4000 Hz, and the air-bone 
gap was compared to the speech recognition threshold 
(SRT) and speech discrimination (PB max). All tests 
were carried out by the same speech and hearing thera-
pist using the same equipment (Maico model MA-41).
Statistical Analysis
Observed variables:
•	Audiometry testing: hearing thresholds by air 
and bone conduction (in dB) were assessed before and 
after drug therapy, as well as air-bone gaps at four fre-
quencies (500 Hz, 1 KHz, 2 KHz, and 4KHz), together 
with speech recognition thresholds (SRT) and speech 
discrimination (PB max).
•	Statistical analysis aimed to compare the 
progress seen in the three study groups before and after 
treatment in terms of their audiometry tests.
Statistical Assessment
The groups were compared for the observed 
variables at one time through Fisher’s exact test for 
qualitative variables and by ANOVA or the Kruskal-
-Wallis test for quantitative variables.
Generalized estimating equation models were 
used to analyze pre and post-treatment quantitative 
variables.
Statistical significance was attributed to results 
whose descriptive levels (p values) were lower than 
0.05.
Statistical assessment was performed with the aid 
of SPSS release 17.0.
RESULTS
The study enrolled 26 patients diagnosed with 
otospongiosis through medical, audiometric, and CT 
imaging examination. Ten of these patients had un-
dergone stapedectomy (10 ears) and these ears were 
excluded from the study. Forty-two ears were thus 
analyzed and divided into groups as follows:
Groups
Group A: nine patients taking placebo - 1 pill/day
Group B: eight patients taking sodium alendro-
nate - 1 pill 10 mg/day
Group C: nine patients taking sodium fluoride - 1 
pill 20 mg/day
Audiometry Testing
Hearing thresholds by air and bone conduction at 
500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz were acquired. 
Pre and post-treatment air-bone gaps, speech recogni-
tion thresholds (SRT), and speech discrimination (PB 
max) were analyzed.
In bone conduction, differences were observed 
only at higher frequencies (2000 and 4000 Hz). At 
2000 Hz, Group A had a greater mean threshold after 
treatment than Group C (p=0.018). However, we must 
point out that such difference already existed prior 
to treatment (p=0.051). At 4000 Hz, the mean values 
observed in Group A were greater than those seen in 
Groups B and C, both pre and post-treatment. At this 
frequency range, only Group A presented a statistically 
significant difference between pre and post-treatment 
values (p=0.008) (Table 1).
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Table 1. Hearing threshold by bone conduction (BC) - mean values and standard error (se) adjusted for the dependency between 





BC 500 Hz- mean (se)
Pre 31.33 (4.13) 28.18 (3.96) 30.0 (3.02)
Post 30.33 (3.84) 27.73 (3.40) 29.33 (3.54)
BC 1K - mean (se)
Pre 34.67 (4.25) 30.91 (5.03) 29.33 (4.63)
Post 35.00 (3.77) 30.00 (3.46) 28.67 (4.34)
BC 2K - mean (se)
Pre 44.33 (3.61) 37.27 (4.15) 34.00 (3.89)
Post 45.00§ (2.67) 37.27 (3.44) 33.33§ (4.14)
BC 4K - mean (se)
Pre 50.00§▲* (3.06) 32.73▲ (6.14) 34.33§ (5.59)
Post 46.00▲* (2.33) 32.27▲ (5.19) 35.00 (5.66)
§ p<0.05 when comparing A to C.
▲ p<0.05 when comparing A to B.
* p<0.05 when comparing Pre to Post.
Table 2. Hearing thresholds by air conduction (AC) - mean values and standard error (se) adjusted for the dependency between 





AC 500 Hz - mean (se)
Pre 62.33* (4.23) 57.73 (3.88) 56.33 (3.82)
Post 60.00* (3.86) 55.45 (4.76) 55.00 (4.14)
AC 1K - mean (se)
Pre 61.33 (5.26) 57.27 (4.42) 55.33 (4.79)
Post 60.33 (4.93) 57.27 (4.99) 57.67 (68.03)
AC 2K - mean (se)
Pre 57.00 (4.66) 51.82 (4.19) 48.00 (5.60)
Post 56.00 (3.84) 50.91 (4.46) 45.67 (5.37)
AC 4K - mean (se)
Pre 72.67▲(3.92) 53.64▲ (6.71) 57.67* (7.73)
Post 70.33▲ (3.75) 55.45▲ (6.33) 54.00* (8.14)
§ p<0.05 when comparing A to C.
▲ p<0.05 when comparing A to B.
* p<0.05 when comparing Pre to Post.
In air conduction at 500 Hz, only Group A 
showed a significant difference between pre and post-
-treatment values (p<0.001). Other differences were seen 
at 4000 Hz, as mean hearing thresholds from Group 
A patients were greater than those seen on Group B 
before and after treatment (p=0.014 and p=0.043 res-
pectively). A difference was also seen on Group C, 
albeit not statistically significant (p=0.083 before and 
p=0.068 after treatment). At 4000 Hz differences were 
seen between pre and post-treatment values only on 
Group C (p<0.001) (Table 2).
Air-bone gap values did not elicit statistically 
significant differences (Table 3). Likewise, speech re-
cognition thresholds (SRT) and speech discrimination 
(PB max) values did not present statistically significant 
differences.
DISCUSSION
The ear capsule presents very little bone remo-
delling, mainly in the sites close to the cochlear and 
vestibular perilymphatic spaces (noble sensorineural 
areas)20.
Otospongiosis is a progressive chronic inflamma-
tory disease that disrupts the labyrinth bone metabolism, 
possibly leading to relevant structural and functional 
damage to the ear capsule and the cochlear/vestibular 
neuroepithelium.
Predicting individual progress in this osteodys-
trophy can be a tall order, despite the various techno-
logical resources available today. It is estimated that 9% 
of the patients with otospongiosis will evolve to deep 
sensorineural hearing loss1,21.
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Indication of drug therapy is done on an each 
case basis. Otospongiosis patients presenting exa-
cerbated signs of disease - Schwartz sign (increased 
vascularity of the promontory secondary to vascular 
congestion caused by an active otosclerotic site); onset 
or worsening of tinnitus and/or vertigo; and progressive 
worsening of sensorineural hearing component - must 
be promptly placed in drug therapy.
The 26 patients in the trial were randomized into 
three groups. Patients in Group A took placebo, those in 
Group B took 10mg of sodium alendronate, and Group 
C patients took 20mg of sodium fluoride for six months. 
Pills were administered in the morning with patients 
fasting (30 minutes before their first morning meal) 
to improve alendronate absorption. As it is a double-
-blind trial, pill administration time was standardized 
for everyone. Only two patients in Group C had mild 
epigastralgia, and were treated with 150mg of ranitidine 
at night. As this adverse reaction is expected, sodium 
fluoride was administered at 20mg/day, once higher 
dosages could lead to the study’s early termination.
Drug therapy efficacy in treating otospongiosis 
patients is still controversial as to the type of medication, 
dosage, and duration of treatment.
Very few randomized controlled trials have 
looked into the efficacy of such drug therapies9,14,17 and 
the literature lacks studies comparing and determining 
the best course of therapy.
The first drug prescribed to treat otospongiosis 
was sodium fluoride, given its track record with other 
osteodystrophies such as osteoporosis and Paget’s 
disease16.
According to the literature, the fluoride dosage 
to treat otospongiosis ranges between 20 and 40mg per 
day, while treatment lasts from six months to two years. 
This dosage is deemed safe in relation to the possible 
undesired effects the drug may cause, principally flu-
orosis, the most severe complication in this therapy. 
Vitamin D and calcium supplementation to prevent 
bone malformation is not required in these cases10.
Sodium fluoride must be administered, prefe-
rably, after a copious meal (lunch or dinner) so that 
gastric discomfort - the most common adverse effect 
with this drug - is minimized. This symptom can be im-
proved with the use of pills with enteric coating or with 
the concomitant administration of calcium carbonate. 
However, fluoride absorption is diminished in these 
cases10. Given the extremely different dosages of the 
two drugs used in this trial, this preventive guideline 
could not be enforced.
Anti-enzyme dosages of sodium fluoride (3-15mg 
per day) - lower than the usual therapy regimes - may 
be indicated to patients presenting persisting signs of 
disease. They may also be used safely for a number of 
years as maintenance therapy10.
Biphosphonates are slowly replacing sodium 
fluoride in the treatment of otospongiosis. Their more 
recent variations (alendronate, risedronate, and iban-
dronate) are more potent anti-resorption agents and do 
not interfere relevantly in bone mineralization when 
compared to etidronate. These drugs may be adminis-
tered orally with the same efficiency either daily (10mg 
alendronate or 5mg risedronate) or once a week15,22,23.
Biphosphonate absorption is harmed when they 
are taken concomitantly to food, and this is why they 
should be preferably administered 30 minutes before the 
first morning meal15. This is why we chose to administer 
drugs while patients were fasting.
Biphosphonates are usually well tolerated when 
administered orally. The main adverse effects are nau-






GAP 500 Hz - mean (se)
Pre 31.00 (3.39) 29.55 (3.19) 26.33 (2.29)
Post 29.67 (3.57) 27.73 (3.40) 26.00 (2.31)
GAP 1K - mean (se)
Pre 26.67 (3.62) 26.36 (2.21) 26.00 (2.68)
Post 25.33 (4.01) 27.27 (2.44) 26.67 (2.80)
GAP 2K - mean (se)
Pre 12.67 (3.41) 14.55 (2.03) 14.00 (2.08)
Post 10.33 (3.18) 15.00 (1.58) 12.33 (2.05)
GAP 4K - mean (se)
Pre 23.00 (3.08) 20.91 (4.03) 22.67 (3.39)
Post 24.33 (2.78) 23.18 (3.66) 20.00 (4.08)
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sea, vomiting, abdominal pain, dyspepsia, diarrhea, ar-
thralgia, and headache. Esophagitis is the most common 
complication, but other gastrointestinal diseases such 
as gastritis, gastric ulcer, and duodenitis may occur15.
The noteworthy scarcity of papers in the literature 
looking at the use of biphosphonates to treat otospongi-
osis makes it harder for one to structure proper, reliable 
therapeutic parameters. In our practice, biphosphonates 
are used from 6 to 12 months. The treatment can be 
repeated if the disease shows relevant signs of activity.
Audiometry test findings indicated a general 
trend towards stabilization of hearing thresholds by 
air and bone conduction. Hearing thresholds by bone 
conduction were statistically reduced at 4000 Hz among 
Group A patients, as were the thresholds by air conduc-
tion at 4000 Hz for Group C subjects (Tables 1 and 2). 
These were punctual findings probably lacking clinical 
relevance. Most patients also presented sensorineural 
involvement, clearly indicating higher disease activ-
ity. In this specific case, the maintenance of hearing 
thresholds during the six months of treatment points 
to stabilization of the injuries caused by otospongiosis. 
Longer treatment would certainly be needed to observe 
substantial improvement or more evident stabilization 
as seen in the audiometry tests.
There was no statistically significant difference 
between air-bone gap, speech recognition threshold 
(SRT), and speech discrimination (PB max) values 
when pre and post-treatment results were compared 
(Tables 3 and 4).
CONCLUSION
After six months of drug therapy, hearing thresh-
olds were maintained and hearing loss levels kept 
stable, probably due to a reduction in disease activity 
on the sites affected by otospongiosis.
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